Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide’s effect on glycemia

American Journal of Physiology - Endocrinology and Metabolism

Volumn 307, Issue 8, 2014, Pages E644-E652

  Ionut, Viorica ^a   Castro, Ana Valeria B ^a   Woolcott, Orison O ^a   Stefanovski, Darko ^a   Iyer, Malini S ^a   Broussard, Josiane L ^a   Burch, Miguel ^a   Elazary, Ram ^a   Kolka, Cathryn M ^a   Mkrtchyan, Hasmik ^a   Bediako, Isaac Asare ^a   Bergman, Richard N ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Denervation; Exenatide; Glucagon like peptide 1; Hepatic portal vein

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; PANCREAS HORMONE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL; PEPTIDE; TYROSINE 3 MONOOXYGENASE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; EXPERIMENTAL DENERVATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INFUSION; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEPATIC PORTAL VEIN DENERVATION; IMPAIRED GLUCOSE TOLERANCE; IMPAIRED ORAL GLUCOSE TOLERANCE; INSULIN INFUSION; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIVER; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PORTAL VEIN; SINGLE DRUG DOSE; AGONISTS; ANALYSIS; ANIMAL; BLOOD; CROSS BREEDING; DENERVATION; DRUG EFFECTS; ENZYMOLOGY; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN RESISTANCE; METABOLISM; PANCREAS ISLET; PATHOPHYSIOLOGY; SECRETION (PROCESS); SUBCUTANEOUS DRUG ADMINISTRATION; SURGERY;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSSES, GENETIC; DENERVATION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; PEPTIDES; PORTAL VEIN; RECEPTORS, GLUCAGON; TYROSINE 3-MONOOXYGENASE; VENOMS;

EID: 84908031942     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00244.2014     Document Type: Article

References (28)

1. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51, Suppl 1: S212-S220, 2002.
2. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5: 1003-1015, 2003.
3. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32: 762-768, 2009.
4. Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 7: e50117, 2012.
5. Donovan CM, Halter JB, Bergman RN. Importance of hepatic glucoreceptors in sympathoadrenal response to hypoglycemia. Diabetes 40: 155-158, 1991.
6. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51: 1584-1592, 2010.
7. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9 -36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356-5363, 1999.
8. Hevener AL, Bergman RN, Donovan CM. Hypoglycemic detection does not occur in the hepatic artery or liver: findings consistent with a portal vein glucosensor locus. Diabetes 50: 399-403, 2001.
9. Hevener AL, Bergman RN, Donovan CM. Portal vein afferents are critical for the sympathoadrenal response to hypoglycemia. Diabetes 49: 8-12, 2000.
10. Ionut V, Castro AV, Woolcott OO, Stefanovski D, Iyer MS, Broussard JL, Mkrtchyan H, Burch M, Elazary R, Kirkman E, Bergman RN. Essentiality of portal vein receptors in hypoglycemic counterregulation: direct proof via denervation in male canines. Endocrinology 155: 1247-1254, 2014.
11. Ionut V, Hucking K, Liberty IF, Bergman RN. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48: 967-975, 2005.
12. Ionut V, Liberty IF, Hucking K, Lottati M, Stefanovski D, Zheng D, Bergman RN. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. Am J Physiol Endocrinol Metab 291: E779-E785, 2006.
13. Ionut V, Zheng D, Stefanovski D, Bergman RN. Exenatide can reduce glucose independent of islet hormones or gastric emptying. Am J Physiol Endocrinol Metab 295: E269-E277, 2008.
14. Jensen KJ, Alpini G, Glaser S. Hepatic nervous system and neurobiology of the liver. Compr Physiol 3: 655-665, 2013.
15. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am J Physiol Endocrinol Metab 293: E1085-E1091, 2007.
16. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24: 275-286, 2008.
17. Matveyenko AV, Donovan CM. Metabolic sensors mediate hypoglycemic detection at the portal vein. Diabetes 55: 1276-1282, 2006.
18. Nauck MA. Unraveling the science of incretin biology. Eur J Intern Med 20, Suppl 2: S303-S308, 2009.
19. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
20. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 61: 149-154, 1996.
21. Pagliassotti MJ, Tarumi C, Neal DW, Cherrington AD. Hepatic denervation alters the disposition of an enteral glucose load in conscious dogs. J Nutr 121: 1255-1261, 1991.
22. Polonsky KS, Pugh W, Jaspan JB, Cohen DM, Karrison T, Tager HS, Rubenstein AH. C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J Clin Invest 74: 1821-1829, 1984.
23. Redondo A, Trigo MV, Acitores A, Valverde I, Villanueva-Peñacarrillo ML. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 204: 43-50, 2003.
24. Sanaka M, Kuyama Y, Yamanaka M. Guide for judicious use of the paracetamol absorption technique in a study of gastric emptying rate of liquids. J Gastroenterol 33: 785-791, 1998.
25. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA. Glucagonlike peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148: 4965-4973, 2007.
26. Watanabe RM, Bergman RN. Accurate measurement of endogenous insulin secretion does not require separate assessment of C-peptide kinetics. Diabetes 49: 373-382, 2000.
27. Yi CX, la Fleur SE, Fliers E, Kalsbeek A. The role of the autonomic nervous liver innervation in the control of energy metabolism. Biochim Biophys Acta 1802: 416-431, 2010.
28. Zheng D, Ionut V, Mooradian V, Stefanovski D, Bergman RN. Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes 58: 352-359, 2009.